Alkermes plc (NASDAQ:ALKS) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers raised its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 464,714 shares of the company’s stock after acquiring an additional 1,683 shares during the quarter. Rhumbline Advisers owned approximately 0.29% of Alkermes worth $13,365,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Centiva Capital LP acquired a new stake in shares of Alkermes in the 3rd quarter valued at about $367,000. Natixis Advisors LLC boosted its position in shares of Alkermes by 190.3% in the 3rd quarter. Natixis Advisors LLC now owns 36,490 shares of the company’s stock valued at $1,021,000 after purchasing an additional 23,921 shares during the period. Sanctuary Advisors LLC boosted its position in shares of Alkermes by 254.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock valued at $944,000 after purchasing an additional 23,541 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Alkermes by 74.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 149,493 shares of the company’s stock valued at $4,184,000 after purchasing an additional 63,939 shares during the period. Finally, Barclays PLC boosted its position in shares of Alkermes by 108.8% in the 3rd quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after purchasing an additional 220,893 shares during the period. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes Price Performance

NASDAQ ALKS opened at $35.33 on Friday. The business has a 50 day moving average price of $30.89 and a 200 day moving average price of $29.07. The company has a market capitalization of $5.74 billion, a P/E ratio of 16.28, a PEG ratio of 2.21 and a beta of 0.49. Alkermes plc has a 1-year low of $22.90 and a 1-year high of $36.45.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. On average, research analysts expect that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ALKS. StockNews.com raised Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft started coverage on Alkermes in a research note on Tuesday, February 11th. They set a “buy” rating and a $40.00 price objective for the company. Mizuho upped their price objective on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and upped their price objective for the company from $25.00 to $36.00 in a research note on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $46.00 price objective on shares of Alkermes in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Alkermes presently has an average rating of “Moderate Buy” and an average target price of $38.36.

Insider Buying and Selling

In other Alkermes news, SVP Christian Todd Nichols sold 5,208 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the completion of the transaction, the senior vice president now owns 60,703 shares of the company’s stock, valued at approximately $1,769,492.45. This trade represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Cato T. Laurencin sold 2,691 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the transaction, the director now directly owns 23,013 shares of the company’s stock, valued at $732,964.05. The trade was a 10.47 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 323,608 shares of company stock valued at $10,854,725. 4.89% of the stock is owned by insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.